Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
797 Real-world treatment duration of atezolizumab+carboplatin+etoposide among older patients with extensive-stage small cell lung cancer (ES-SCLC) and the impact of performance status and brain metastases
Compose a Response to This Article
Other responses
No responses have been published for this article.